SCHEMBL687914

SCHEMBL687914

CC(=O)c1ccc(O)cc1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 1/20 0.46
ALDH1A1 P00352 3/20 0.46
HPGD P15428 2/20 0.46
CYP3A4 P08684 1/20 0.46
MAPK1 P28482 1/20 0.46
CES2 O00748 1/20 0.45
CA12 O43570 5/20 0.43
CA1 P00915 5/20 0.43
CA2 P00918 5/20 0.43
CA7 P43166 5/20 0.43
CA9 Q16790 5/20 0.43
CA14 Q9ULX7 5/20 0.43
TSHR P16473 1/20 0.43
MAOB P27338 3/20 0.43
GAA P10253 3/20 0.43
MAPT P10636 2/20 0.43
KDM4E B2RXH2 2/20 0.43
GLA P06280 2/20 0.43
MEN1 O00255 1/20 0.43
S1PR4 O95977 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14978296 0.83 ALDH1A1 (0.46) HSD17B1ALDH1A1HPGDCYP3A4MAPK1
SCHEMBL10779237 0.82 CES2 (0.48) ALDH1A1HPGDMAPK1CES2CA12
SCHEMBL10545761 0.82 CES2 (0.60) ALDH1A1MAPK1CES2CA12CA1
SCHEMBL7065849 0.80 CA12 (0.61) ALDH1A1CES2CA12CA1CA2
SCHEMBL1312703 0.80 L3MBTL1 (0.47) ALDH1A1HPGDMAPK1CES2TSHR
SCHEMBL29530881 0.80 L3MBTL1 (0.47) ALDH1A1HPGDMAPK1CES2TSHR
SCHEMBL16520525 0.79 ALDH1A1 (0.55) HSD17B1ALDH1A1HPGDCYP3A4MAPK1
SCHEMBL1329346 0.78 CYP2A6 (0.42) ALDH1A1HPGDMAPK1GAAMAPT
SCHEMBL27947531 0.78 ERN1 (0.47) ALDH1A1HPGDMAPK1CES2CA12
SCHEMBL27838132 0.78 CES2 (0.45) ALDH1A1MAPK1CES2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078296-A1 SUSTAINED-RELEASE SCALE INHIBITORS Materials Engineering and Technical Support Services (US) 2026-03-19 US claimed
WO-2024059615-A2 SUSTAINED-RELEASE SCALE INHIBITORS MATERIALS ENGINEERING AND TECHNICAL SUPPORT SERVICES CORPORATION (US) 2024-03-21 WO claimed
CN-115557865-A Thioether-promoted cysteine-based bioconjugation method 南京工业大学 2023-01-03 CN claimed
US-10323051-B2 Methods for controlling depolymerization of polymer compositions RHODIA OPERATIONS (FR) 2019-06-18 US claimed
EP-2707376-B1 METHODS FOR CONTROLLING DEPOLYMERIZATION OF POLYMER COMPOSITIONS RHODIA OPERATIONS (FR) 2016-11-30 EP claimed
US-20150338414-A1 UREA-BASED SYNTHETIC URINE AND METHOD OF MANUFACTURING SAME SPECTRUM LABORATORIES, LLC 2015-11-26 US claimed
US-9128105-B2 Urea-based synthetic urine and method of manufacturing same SPECTRUM LABORATORIES, LLC (US) 2015-09-08 US claimed
US-20140329327-A1 UREA-BASED SYNTHETIC URINE AND METHOD OF MANUFACTURING SAME SPECTRUM LABORATORIES, LLC 2014-11-06 US claimed
CN-103797019-A Method for controlling depolymerization of polymer compositions RHODIA OPERATIONS 2014-05-14 CN claimed
EP-2707376-A2 METHODS FOR CONTROLLING DEPOLYMERIZATION OF POLYMER COMPOSITIONS Rhodia Operations S.A. (FR) 2014-03-19 EP claimed
US-20090133810-A1 Production method and filter comprising non woven fabric and/or filtering injector structures or sheets which are obtained using said method and which are intended for the filtration and elimination of legionella pneumophila in any installation at risk from legionella pneumophila proliferation PENALVA JOAQUIN ESPUELAS 2009-05-28 US claimed
US-20070202770-A1 Production Method and Filter Comprising Non Woven Fabric and/or Filtering Injector Structures or Sheets Which are Obtained Using Said Method and Which are Intended for the Filtration and Which are Intended for the Filtration and Elimination of Legionella Pneumofila in any Installation at Risk From Legionella Pneumofila Proliferation PENALVA JOAQUIN E 2007-08-30 US claimed
US-20070095763-A1 Uncoupling agents RHODIA RECHERCHES ET TECHNOLOGIES (FR) 2007-05-03 US claimed
US-7192776-B2 Synthetic urine and method of manufacturing same SPECTRUM LABORATORIES, LLC 2007-03-20 US claimed
EP-1738812-A1 PRODUCTION METHOD, AND FILTER COMPRISING NON-WOVEN FABRIC AND/OR FILTERING INJECTOR STRUCTURES OR SHEETS WHICH ARE OBTAINED USING SAID METHOD AND WHICH ARE INTENDED FOR THE FILTRATION AND ELIMINATION OF LEGIONELLA PNEUMOPHILA IN ANY INSTALLATION WITH A RISK OF LEGIONELLA PNEUMOPHILA PROLIFERATION Espuelas Peñalva, Joaquin (ES) 2007-01-03 EP claimed
EP-1638895-A2 UNCOUPLING AGENTS Rhodia UK Limited (GB) 2006-03-29 EP claimed
WO-2004113236-A2 UNCOUPLING AGENTS RHODIA UK LTD (GB) 2004-12-29 WO claimed
US-6770677-B2 FOR PAINTS, ADHESIVES, WATER TREATMENT; BACTERICIDES, FUNGICIDES, MICROBIOCIDES VERICHEM, INC. 2004-08-03 US claimed
US-20030156979-A1 Synergistic mixtures of Bis (Trichloromethyl) Sulfone and 1,2-dibromo-2,4-dicyanobutane VERICHEM, INC. 2003-08-21 US claimed
WO-2003066773-A2 SYNERGISTIC MIXTURES OF BIS (TRICHLOROMETHYL) SULFONE AND 1,2-DIBROMO-2, 4-DICYANOBUTANE VERICHEM, INC. (US) 2003-08-14 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078296-A1 SUSTAINED-RELEASE SCALE INHIBITORS CEL, TST, CD44 HSD17B1 524/4885ALDH1A1 1392/4885HPGD 1824/4885
US-10323051-B2 Methods for controlling depolymerization of polymer compositions DDOST, POLI, FYN HSD17B1 3171/4885ALDH1A1 3571/4885HPGD 4015/4885
US-20030156979-A1 Synergistic mixtures of Bis (Trichloromethyl) Sulfone and 1,2-dibromo-2,4-dicyanobutane DPM1, PBRM1, SULT1E1 HSD17B1 3117/4885ALDH1A1 2051/4885HPGD 4307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.